SHSE:603193 (China)
Â
Ordinary Shares - Class A
Â¥
19.54
-0.040 (-0.2%)
Sep 15
Business Description
Runben Biotechnology Co Ltd
SIC : 2844
ISIN : CNE100006DK5
Share Class Description:
SHSE:603193: Ordinary Shares - Class ATotal Employee Number:
1,018Compare
Compare
Traded in other countries / regions
603193.China Index Membership
SSE Composite Index IPO Date
2023-10-17Description
Runben Biotechnology Co Ltd is engaged in the research & development, production and sales of mosquito repellent and personal care products.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2142.15 | |||||
Equity-to-Asset | 0.92 | |||||
Interest Coverage | 6849.96 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 24.62 | |||||
Beneish M-Score | -2.38 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 15.1 | |||||
3-Year EBITDA Growth Rate | 15.8 | |||||
3-Year EPS without NRI Growth Rate | 15.6 | |||||
3-Year FCF Growth Rate | 8.3 | |||||
3-Year Book Growth Rate | 37.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 18.36 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 18.64 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 31.63 | |||||
9-Day RSI | 36.6 | |||||
14-Day RSI | 40.75 | |||||
3-1 Month Momentum % | -4.31 | |||||
6-1 Month Momentum % | -7.69 | |||||
12-1 Month Momentum % | -26.87 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 8.74 | |||||
Quick Ratio | 7.95 | |||||
Cash Ratio | 7.35 | |||||
Days Inventory | 78.58 | |||||
Days Sales Outstanding | 10.46 | |||||
Days Payable | 51.87 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 2.35 | |||||
Dividend Payout Ratio | 0.53 | |||||
Forward Dividend Yield % | 2.35 | |||||
5-Year Yield-on-Cost % | 2.35 | |||||
3-Year Average Share Buyback Ratio | -5.6 | |||||
Shareholder Yield % | 2.42 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 59.83 | |||||
Operating Margin % | 22.12 | |||||
Net Margin % | 20.67 | |||||
EBITDA Margin % | 23.58 | |||||
FCF Margin % | 15.67 | |||||
OCF Margin % | 19.4 | |||||
ROE % | 15.74 | |||||
ROA % | 14.71 | |||||
ROIC % | 31.88 | |||||
3-Year ROIIC % | 19.42 | |||||
ROC (Joel Greenblatt) % | 65.17 | |||||
ROCE % | 17.93 | |||||
Years of Profitability over Past 10-Year | 7 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 22.2 | |||||
Forward PE Ratio | 17.74 | |||||
PE Ratio without NRI | 22.33 | |||||
Price-to-Owner-Earnings | 27.28 | |||||
PEG Ratio | 1.03 | |||||
PS Ratio | 4.57 | |||||
PB Ratio | 3.37 | |||||
Price-to-Tangible-Book | 3.51 | |||||
Price-to-Free-Cash-Flow | 31.23 | |||||
Price-to-Operating-Cash-Flow | 23.54 | |||||
EV-to-EBIT | 15.92 | |||||
EV-to-EBITDA | 15.92 | |||||
EV-to-Revenue | 3.75 | |||||
EV-to-FCF | 25.74 | |||||
Price-to-GF-Value | 0.68 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.24 | |||||
Price-to-Graham-Number | 1.87 | |||||
| Price-to-Net-Current-Asset-Value | 4.99 | |||||
| Price-to-Net-Cash | 6.07 | |||||
Earnings Yield (Greenblatt) % | 6.28 | |||||
FCF Yield % | 3.14 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Runben Biotechnology Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 1,703.552 | ||
| EPS (TTM) (Â¥) | 0.87 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 35.61 | ||
| 14-Day RSI | 40.75 | ||
| 14-Day ATR (Â¥) | 0.777092 | ||
| 20-Day SMA (Â¥) | 20.7195 | ||
| 12-1 Month Momentum % | -26.87 | ||
| 52-Week Range (Â¥) | 17.77 - 30 | ||
| Shares Outstanding (Mil) | 404.59 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Runben Biotechnology Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Runben Biotechnology Co Ltd Stock Events
| Event | Date | Price (Â¥) | ||
|---|---|---|---|---|
| CNY 0.260000 Cash Dividend | 2026-05-29 | 21.78 (-1.40%) | ||
| CNY 0.200000 Cash Dividend | 2025-09-18 | 28.77 (-0.14%) | ||
| CNY 0.230000 Cash Dividend | 2025-05-30 | 38.76 (-3.32%) | ||
| CNY 0.180000 Cash Dividend | 2024-10-30 | 24.56 (-0.69%) |
Show
Entries
Runben Biotechnology Co Ltd Frequently Asked Questions
What is Runben Biotechnology Co Ltd(SHSE:603193)'s stock price today?
The current price of SHSE:603193 is ¥19.54. The 52 week high of SHSE:603193 is ¥30.00 and 52 week low is ¥17.77.
When is next earnings date of Runben Biotechnology Co Ltd(SHSE:603193)?
The next earnings date of Runben Biotechnology Co Ltd(SHSE:603193) is .
Does Runben Biotechnology Co Ltd(SHSE:603193) pay dividends? If so, how much?
The Dividend Yield %  of Runben Biotechnology Co Ltd(SHSE:603193) is 2.35% (As of Today), Highest Dividend Payout Ratio of Runben Biotechnology Co Ltd(SHSE:603193) was 0.59. The lowest was 0.49. And the median was 0.54. The  Forward Dividend Yield % of Runben Biotechnology Co Ltd(SHSE:603193) is 2.35%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers